MOR MorphoSys Corp Gross Profit Margin

MOR (MorphoSys Corporation) - company brandmark

Following the completion of the holding's acquisition and program integration, the analytical chart on GURU.Markets includes a gross margin ratio, where 75.90 determines this parameter level. MorphoSys AG (MOR) relies on its patent portfolio and pelabresib trials in the R&D race. Laboratories in the US and Germany are developing oncology therapies, the stability of which is guaranteed by its status as a subsidiary of a global leader.

MOR MorphoSys Corp Return on Gross Profit (07/04/2022 - 08/10/2024)

Comprehensive metric breakdowns and analytics for MorphoSys AG (MOR)

- stock price and consensus target price:
Fundamental valuation:MorphoSys AG
Mass-produced product of MorphoSys Corporation

For MorphoSys AG (MOR), which is integrating its oncology developments into the structure of a pharma behemoth, the gross margin serves as an indicator of direct cost management efficiency. This metric is calculated as the share of revenue minus the cost of goods sold, demonstrating the business's ability to generate profit before accounting for operating expenses. By analyzing the current gross margin level, an investor can identify anomalies in drug production costs against the backdrop of the asset merger.

Direct competitors

Gross Profit Margin BeiGene Ltd. (ONC)|Return on Gross Profit HALO|Gross Profitability RVMD|Return on Gross Profit AAPG (Ascentage)|Return on Gross Profit cgoncology.com CGON|UroGen Pharma - Return on Gross Profit|Gross Profit Rate BCAX|PSNL - Gross Profitability|Return on Sales by Gross Profit Erasca Oncology ERAS|delcath.com (DCTH) - Gross Profitability|Y-mAbs Therapeutics - Gross Profit Rate|AURA (Aura Biosciences Inc) - Gross Margin|Gross Profit Margin candeltx.com CADL|Gross Margin ARAY|SLS (SELLAS Life Sciences Group, Inc.) - Gross Profit Rate|Gross Profitability Actuate Therapeutics, Inc. ACTU|citiusonc.com - Gross Profitability|TuHURA Biosciences Inc. - Gross Margin|TARA - Gross Margin|FATE (Fate Therapeutics) - Return on Gross Profit|Return on Gross Profit Aadi Bioscience, Inc.|Return on Gross Profit TCRX|Gross Profitability CSBR|Gross Margin XBIT|Return on Sales by Gross Profit CEL-SCI Corp.|Gross Profitability ostherapies.com OSTX|RADX: Gross Return on Sales|ARTV: Return on Gross Profit|ANL (Adlai Nortye) - Gross Return on Sales|Veru (VERU) - Gross Profitability|Return on Gross Profit Tempest Therapeutics Inc|Gross Profitability Xilio Therapeutics|Gross Return on Sales RENB (Renovaro Inc.)|Gross Profitability Mural Oncology PLC (MURA)|Gross Margin Kairos Pharma (KAPA)|Gross Profitability onkuretherapeutics.com OKUR|GDTC: Gross Return on Sales|CRIS: Return on Gross Profit|apollomicsinc.com (APLM) - Return on Gross Profit|THAR: Gross Margin|Return on Gross Profit Advanced Biomed Inc.|Return on Gross Profit GNPX|Gross Return on Sales CLDI (Calidi Biotherapeutics)|Gross Margin SBFM|Xenetic Biosciences, Inc. - Gross Return on Sales|Gross Profitability Salarius Pharmaceuticals SLRX|Gross Margin purple-biotech.com PPBT|AONC - Gross Profitability|BGNE: Gross Profitability|CKPT: Gross Margin|Elevation Oncology - Gross Profit Rate|ICAD (iCAD) - Gross Margin|IKNA: Gross Profit Rate|Gross Profitability Notable Labs (NTBL)|VIRX (Viracta Therapeutics, Inc.) - Gross Profit Rate|Gross Profitability NAYA Biosciences NAYA|AAPGV - Return on Gross Profit